Qing-Qing Qiu

Qing-Qing Qiu

Auto-generated profile, based on publicly available information

Qing-Qing Qiu

Stryker, 2825 Airview Boulevard, Kalamazoo, MI, 49002, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Regulatory Toxicology and Pharmacology
Verified
Journal Article
Open access
MKMichael Kovochich
Michael Kovochich
AMAndrew Monnot
Andrew Monnot
DKDaniel G. Kougias
Daniel G. Kougias
SMSharlee L. More
Sharlee L. More
JWJared T. Wilsey
Jared T. Wilsey
GEGary Eichenbaum
Gary Eichenbaum
Cobalt (Co) alloys have been used for over seven decades in a wide range of medical devices, including, but not limited to, hip and knee implants, surgical tools, and vascular stents, due to their favorable biocompatibility, durability, and mechanical properties. A recent regulatory hazard classification review by the European Chemicals Agency (ECHA) resulted in the classification of metallic Co as a Class 1B Carcinogen (presumed to have carcinogenic potential for humans), primarily based on inhalation rodent carcinogenicity studies with pure metallic Co. The ECHA review did not specifically consider the carcinogenicity hazard potential of forms or routes of Co that are relevant for medical devices. The purpose of this review is to present a comprehensive assessment of the available in vivo preclinical data on the carcinogenic hazard potential of exposure to Co-containing alloys (CoCA) in medical devices by relevant routes. In vivo data were reviewed from 33 preclinical studies that examined the impact of Co exposure on local and systemic tumor incidence in rats, mice, guinea pigs, and hamsters. Across these studies, there was no significant increase of local or systemic tumors in studies relevant for medical devices. Taken together, the relevant in vivo data led to the conclusion that CoCA in medical devices are not a carcinogenic hazard in available in vivo models. While specific patient and implant factors cannot be fully replicated using in vivo models, the available in vivo preclinical data support that CoCA in medical devices are unlikely a carcinogenic hazard to patients.

1 October 2021 in Regulatory Toxicology and Pharmacology
Verified
Journal Article
Open access
GEGary Eichenbaum
Gary Eichenbaum
JWJared T. Wilsey
Jared T. Wilsey
GFGion Fessel
Gion Fessel
QQQing-Qing Qiu
Qing-Qing Qiu
LPLaura Perkins
Laura Perkins
KUKenneth Unice
Kenneth Unice
In 2017, the European Union (EU) Committee for Risk Assessment (RAC) recommended the classification of metallic cobalt (Co) as Category 1B with respect to its carcinogenic and reproductive hazard potential and Category 2 for mutagenicity but did not evaluate the relevance of these classifications for patients exposed to Co-containing alloys (CoCA) used in medical devices. CoCA are inherently different materials from Co metal from a toxicological perspective and thus require a separate assessment. CoCA are biocompatible materials with a unique combination of properties including strength, durability, and a long history of safe use that make them uniquely suited for use in a wide-range of medical devices. Assessments were performed on relevant preclinical and clinical carcinogenicity and reproductive toxicity data for Co and CoCA to meet the requirements under the EU Medical Device Regulation triggered by the ECHA re-classification (adopted in October 2019 under the 14th Adaptation to Technical Progress to CLP) and to address their relevance to patient safety. The objective of this review is to present an integrated overview of these assessments, a benefit-risk assessment and an examination of potential alternative materials. The data support the conclusion that the exposure to CoCA in medical devices via clinically relevant routes does not represent a hazard for carcinogenicity or reproductive toxicity. Additionally, the risk for the adverse effects that are known to occur with elevated Co concentrations (e.g., cardiomyopathy) are very low for CoCA implant devices (infrequent reports often reflecting a unique catastrophic failure event out of millions of patients) and negligible for CoCA non-implant devices (not measurable/no case reports). In conclusion, the favorable benefit-risk profile also in relation to possible alternatives presented herein strongly support continued use of CoCA in medical devices.

20 July 2022 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
PDF file
HDH.L. Dingwall
H.L. Dingwall
RTR.R. Tomizawa
R.R. Tomizawa
BKB. Kokalari
B. Kokalari
QQQ. Qiu
Q. Qiu
PHPeng Hu
Peng Hu
YKY.G. Kamberov
Y.G. Kamberov